Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
The Mark H. Zangmeister Center
mi
from
Columbus, OH
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
The Mark H. Zangmeister Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Oregon Health and Science University
mi
from
Portland, OR
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
The West Clinic, PC
mi
from
Memphis, TN
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Texas Oncology, PA
mi
from
Dallas, TX
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Texas Oncology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Utah Cancer Specialists
mi
from
Salt Lake City, UT
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Utah Cancer Specialists
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Virginia Oncology Associates
mi
from
Norfolk, VA
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Virginia Cancer Institute
mi
from
Richmond, VA
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Virginia Cancer Institute
mi
from
Richmond, VA
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
SUNY Upstate Medical University
mi
from
Syracuse, NY
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Status: Enrolling
Updated:  1/14/2016
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Status: Enrolling
Updated: 1/14/2016
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Status: Enrolling
Updated:  1/14/2016
Memoral Sloan Kettering Cancer Center@Phelps
mi
from
Sleepy Hollow, NY
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Status: Enrolling
Updated: 1/14/2016
Memoral Sloan Kettering Cancer Center@Phelps
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Status: Enrolling
Updated:  1/14/2016
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Status: Enrolling
Updated: 1/14/2016
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Status: Enrolling
Updated:  1/14/2016
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Status: Enrolling
Updated: 1/14/2016
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Status: Enrolling
Updated:  1/14/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Status: Enrolling
Updated: 1/14/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
A Phase 1 Study of [14C]- IXAZOMIB (MLN9708) to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphomas
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Cleveland, OH
Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
A Phase 1 Study of [14C]- IXAZOMIB (MLN9708) to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphomas
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
An Investigator Sponsored Phase 1a/1b Trial of Selinexor in Combination With Irinotecan in Patients With Adenocarcinoma of Stomach and Distal Esophagus
Status: Enrolling
Updated:  1/14/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
An Investigator Sponsored Phase 1a/1b Trial of Selinexor in Combination With Irinotecan in Patients With Adenocarcinoma of Stomach and Distal Esophagus
Status: Enrolling
Updated: 1/14/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
PET/MRI and PET/CT in Diagnosing Younger Patients With Cancer
Clinical Evaluation of PET-MRI Versus PET-CT in Pediatric Oncology Patients
Status: Enrolling
Updated:  1/14/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
PET/MRI and PET/CT in Diagnosing Younger Patients With Cancer
Clinical Evaluation of PET-MRI Versus PET-CT in Pediatric Oncology Patients
Status: Enrolling
Updated: 1/14/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
WISER After Ovarian Cancer - Exercise Pilot Study
WISER After Ovarian Cancer - Exercise Pilot Study
Status: Enrolling
Updated:  1/14/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
WISER After Ovarian Cancer - Exercise Pilot Study
WISER After Ovarian Cancer - Exercise Pilot Study
Status: Enrolling
Updated: 1/14/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors
Phase I Study Of Gemcitabine, Docetaxel And Carboplatin, With And Without Filrastim Support, Combination Chemotherapy In Patients With Advanced Non-Hematological Malignancies
Status: Enrolling
Updated:  1/14/2016
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors
Phase I Study Of Gemcitabine, Docetaxel And Carboplatin, With And Without Filrastim Support, Combination Chemotherapy In Patients With Advanced Non-Hematological Malignancies
Status: Enrolling
Updated: 1/14/2016
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Helen F. Graham Cancer Center
mi
from
Newark, DE
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Helen F. Graham Cancer Center
mi
from
Newark, DE
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Rush-Presbyterian-St. Luke's Medical Center
mi
from
Chicago, IL
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Rush-Presbyterian-St. Luke's Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
IN Onc/Hem Associates
mi
from
Indianapolis, IN
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
IN Onc/Hem Associates
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Indiana University Cancer Center
mi
from
Indianapolis, IN
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Quality Cancer Center (MCGOP)
mi
from
Indianapolis, IN
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Quality Cancer Center (MCGOP)
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Medical Consultants, P.C.
mi
from
Muncie, IN
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Medical Consultants, P.C.
mi
from
Muncie, IN
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Siteman Cancer Center
mi
from
St. Louis, MO
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Methodist Cancer Center
mi
from
Omaha, NE
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Methodist Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
A Multicenter, Phase II Open-Labeled, Single-Arm Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/14/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
A Multicenter, Phase II Open-Labeled, Single-Arm Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/14/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Combination Paclitaxel, Carboplatin and Temozolomide
Phase I Dose Finding Clinical Trial of Combination Paclitaxel, Carboplatin and Temozolomide for Subjects With Solid Tumor Malignancies.
Status: Enrolling
Updated:  1/15/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Combination Paclitaxel, Carboplatin and Temozolomide
Phase I Dose Finding Clinical Trial of Combination Paclitaxel, Carboplatin and Temozolomide for Subjects With Solid Tumor Malignancies.
Status: Enrolling
Updated: 1/15/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  1/15/2016
Cancer Center at Presbyterian Hospital
mi
from
Albuquerque, NM
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 1/15/2016
Cancer Center at Presbyterian Hospital
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  1/15/2016
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 1/15/2016
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  1/15/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 1/15/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  1/15/2016
University of New Mexico Cancer Center @ Lovelace Medical Center
mi
from
Albuquerque, NM
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 1/15/2016
University of New Mexico Cancer Center @ Lovelace Medical Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  1/15/2016
Memorial Medical Center- Cancer Center
mi
from
Las Cruces, NM
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 1/15/2016
Memorial Medical Center- Cancer Center
mi
from
Las Cruces, NM
Click here to add this to my saved trials
Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer
Ovarian Cancer Early Detection Screening Program
Status: Enrolling
Updated:  1/15/2016
Marsha Rivkin Center for Ovarian Cancer Research
mi
from
Seattle, WA
Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer
Ovarian Cancer Early Detection Screening Program
Status: Enrolling
Updated: 1/15/2016
Marsha Rivkin Center for Ovarian Cancer Research
mi
from
Seattle, WA
Click here to add this to my saved trials
Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies
A Phase 1 Protocol of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies
Status: Enrolling
Updated:  1/15/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies
A Phase 1 Protocol of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies
Status: Enrolling
Updated: 1/15/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status: Enrolling
Updated:  1/15/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status: Enrolling
Updated: 1/15/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status: Enrolling
Updated:  1/15/2016
University of New Mexico Cancer Center @ Lovelace Medical Center
mi
from
Albuquerque, NM
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status: Enrolling
Updated: 1/15/2016
University of New Mexico Cancer Center @ Lovelace Medical Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status: Enrolling
Updated:  1/15/2016
Cancer Center at Presbyterian Hospital
mi
from
Albuquerque, NM
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status: Enrolling
Updated: 1/15/2016
Cancer Center at Presbyterian Hospital
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated:  1/15/2016
Yale University School of Medicine
mi
from
New Haven, CT
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated: 1/15/2016
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated:  1/15/2016
Florida Cancer Specialists - South
mi
from
Fort Myers, FL
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)
Status: Enrolling
Updated: 1/15/2016
Florida Cancer Specialists - South
mi
from
Fort Myers, FL
Click here to add this to my saved trials